
Rigel Pharmaceuticals (RIGL) Stock Forecast & Price Target
Rigel Pharmaceuticals (RIGL) Analyst Ratings
Bulls say
Rigel Pharmaceuticals is viewed positively because it is transitioning into a multi-product commercial-stage company with narrower 2024 revenue guidance of $290M-$295M, while also ending the quarter with about $99M in cash and equivalents and guiding to positive net income for the full year. The first reported quarter of VEPPANU showed $6.6M in net product sales from mid-August to quarter-end, shipment to 100+ patients/clinics, and strong refill rates, which supports the thesis that real-world physician experience could drive substantial uptake. In addition, Gavreto’s clinical activity across RET fusion-positive tumors, including a 53% overall response rate in pooled solid tumors and 88% in previously treated pancreatic cancer, alongside encouraging R289 signals, reinforces the company’s diversified growth potential.
Bears say
Rigel Pharmaceuticals is facing a negative fundamental setup because its lead asset fostamatinib recently missed the primary endpoint in the pivotal warm AIHA trial, weakening confidence in clinical success and raising the risk of regulatory rejection or the need for additional studies. The company also remains highly exposed to stringent FDA and international oversight, while commercialization of its approved products is vulnerable to competitive pressure in ITP and to physicians’ reluctance to switch from established therapies. With a narrow pipeline concentrated in risky development-stage programs, limited execution would further diminish the drug’s market potential and the broader investment case.
This aggregate rating is based on analysts' research of Rigel Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Rigel Pharmaceuticals (RIGL) Analyst Forecast & Price Prediction
Start investing in Rigel Pharmaceuticals (RIGL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Rigel Pharmaceuticals (RIGL) Forecast
Rigel Pharmaceuticals (RIGL) Analyst Forecast & Price Prediction
Start investing in Rigel Pharmaceuticals (RIGL)
Order type
Buy in
Order amount
Est. shares
0 shares